Therapy Areas: Inflammatory Diseases
Celltrion launches AVTOZMA IV in the United States following FDA approval
2 October 2025 - South Korea-based Celltrion, Inc., a global biopharmaceutical company, announced on Thursday that it has launched AVTOZMA (CT-P47, tocilizumab-anoh) intravenous formulation in the Uni...
Novartis to launch US direct-to-patient platform for Cosentyx
30 September 2025 - Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) announced on Monday that it plans to launch a direct-to-patient (DTP) platform in the United States which will...
Vascarta completes VAS-101 osteoarthritis clinical trial
30 September 2025 - Vascarta Inc, a clinical-stage biopharmaceutical company focused on innovative treatments for pain and inflammation, announced on Monday the successful completion of its phase 1 cl...
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
29 September 2025 - Anti-inflammatory therapeutics developer Sen-Jam Pharmaceutical announced on Friday that, in collaboration with pharmaceutical manufacturer KVK Tech, it has completed the final dev...
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
26 September 2025 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) announced on Friday that it has agreed a strategic partnership with Inserm Transfert (on behalf of Inser...
ResVita Bio completes face-to-face Pre-IND meeting with FDA for RVB-003
25 September 2025 - ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, announced on Wednesday that it has completed a face-to-face Pre-Investigational New Dr...